Solventum cash flow statement

In fiscal 2025, Solventum's operations generated $369m of cash; it spent $379m on capital projects, leaving free cash flow of −$10.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Solventum: cash flow statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	1,679	1,915	1,185	369	209
Depreciation and amortisation	578	561	555	489	325
Stock-based pay	37	39	112	161	167
Capital spending	251	290	380	379	327
Free cash flow	1,428	1,625	805	−10	−118
Free cash flow after stock pay	1,391	1,586	693	−171	−285

US$ millions unless shown otherwise. Fiscal quarters.

Solventum: cash flow statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	169	219	29	169	76	95	−189	227
Depreciation and amortisation	37	150	129	38	37	117	135	36
Stock-based pay	27	25	49	34	41	37	51	38
Capital spending	93	127	109	110	97	63	84	83
Free cash flow	76	92	−80	59	−21	32	−273	144
Free cash flow after stock pay	49	67	−129	25	−62	−5	−324	106

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: SOLV vs VEEV SOLV vs TDOC SOLV vs TEM

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Solventum's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Solventum.